Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Survival outcomes and characterization of mCSPC

Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, provides an overview of the survival outcomes and characterization of patients with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response. Only a minority of patients with mCSPC do not achieve an optimal PSA response with intensified ADT. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.